Table 3.
Evaluable patient outcomes and time to progression
| Cohort 1 | Cohort 2 | Total | |||
|---|---|---|---|---|---|
| Rising PSA | Metastatic | Rising PSA | Metastatic | ||
|
Treatment-specific undetectable PSA outcome | |||||
| No. evaluable | 25 | 37 | 17 | 21 | 100 |
| 6 monthsa, No. (%) | 9 (36%) | 14 (38%) | 13 (76%) | 12 (57%) | 48 (48%) |
| 18 months, No. (%) | 0 | 0 | 3 (18%) | 2 (10%) | 5b (5%) |
|
Time to progression | |||||
|---|---|---|---|---|---|
| Rising PSA | Metastatic | Rising PSA | Metastatic | Total | |
| No. evaluable | 25 | 37 | 14 | 19 | 95c |
| Median, months | 9 | 10 | 14 | 13 | 13 |
| Range, months | 8–15 | 8–14 | 11–19 | 6–21 | 8–21 |
a
6 28-day docetaxel cycles for cohort 1 and 9 21-day docetaxel cycles for cohort 2.
b
All 5 patients achieved an undetectable PSA by cycle 6.
c
5 patients in cohort 2 remain on study at a median of 23+ months (range 18+ to 26+)